Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: Results from a pilot study

Leukemia

Volumn 14, Issue 9, 2000, Pages 1583-1588

  Hofmann, W K ^a   Kell, W J ^b   Fenaux, P ^c   Castaigne, S ^d   Ganser, A ^e   Chomienne, C ^f   Burnett, R ^g   Kowal, C ^h   Hoelzer, D ^a   Burnett, A K ^b  

^a GOETHE UNIVERSITY   (Germany)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c Service des Maladies du Sang   (France)

^d CENTRE HOSPITALIER DE VERSAILLES   (France)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f SAINT LOUIS HOSPITAL   (France)

^g ALLERGAN PLC   (United States)

^h LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

9 Cis retinoic acid; Differentiation therapy; Myelodysplastic syndrome

Indexed keywords

ALITRETINOIN; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD TRANSFUSION; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFICACY; DRUG FORMULATION; DRUG RECEPTOR BINDING; DRY SKIN; FEMALE; HEADACHE; HUMAN; LEUKOCYTE COUNT; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; RASH; RECEPTOR UPREGULATION; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; TREATMENT OUTCOME;

EID: 0033828610     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401873     Document Type: Article

References (47)

1. Developmental roles of the retinoic acid receptors
2. Retinoic acid receptors in normal growth and development
3. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
4. Regulation and regulatory role of the retinoids
5. Mechanisms of transactivation by retinoic acid receptors
6. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25-dihydroxyvitamin D3, and analogs
7. A human retinoic acid receptor which belongs to the family of nuclear receptors
8. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus
9. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
10. Nuclear receptor that identifies a novel retinoic acid response pathway
11. 3 signalling
12. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes
13. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes
14. Myelodysplastic syndromes: Clinical features
15. Induction of TNF-alpha in patients with myelodysplastic syndromes undergoing treatment with interleukin-3
16. Apoptosis and its significance in MDS: Controversies revisited
17. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: Possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome
18. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome
19. What is ineffective erythropoiesis in myelodysplastic syndromes?
20. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes
21. + cells
22. Differentiation therapy in myelodysplastic syndromes
23. Effect of combination therapy with all-trans retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes
24. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
25. Combined differentiating therapy for myelodysplastic syndromes: A phase II study
26. 3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study
27. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans retinoic acid, granulocyte colony-stimulating factor, erythropoietin and alpha-tocopherol
28. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes
29. Differentiation therapy of myelodysplastic syndromes: Fact or fiction?
30. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
31. 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXR alpha
32. Vitamin A receptors
33. The retinoid receptors
34. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells
35. 9-cis-retinoic acid: Effects on normal and leukemic hematopoiesis in vitro
36. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid
37. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer
38. Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia
39. Proposals for the classification of the myelodysplastic syndromes
40. International scoring system for evaluating prognosis in myelodysplastic syndromes
41. Randomized study of 13-cis retinoic acid vs placebo in the myelodysplastic disorders
42. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol
43. All-trans retinoic acid in the treatment of myelodysplastic syndromes
44. All-trans retinoic acid in patients with myelodysplastic syndromes: Results of a pilot study
45. 3 and retinoic acid in acute leukemia and myelodysplastic syndromes
46. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro
47. Differentiation-inducing agents in the treatment of myelodysplastic syndromes